Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Olema Pharmaceuticals enters the week of October 18 with a fresh activist filing on its register, a stock down 33% in a month, and shorts holding nearly 20% of the float as the next data readout approaches in three weeks.
The most newsworthy development on the register is BVF Partners filing a Schedule 13D on October 16, the day of this snapshot. BVF held 9.8% of the class as last disclosed, but the switch from a passive 13G to a 13D signals the firm now intends to engage actively with the company rather than simply hold. That is one of the highest-signal events in the 13D/G register. Logos Global Management also carries a 13D designation, filed in May 2025, at a stake that has since dipped to 4.7% of the class. As the standard caveat applies: positions on the 13D/G register are as last disclosed around the 5% threshold, and a holder dropping below that level may exit without a further filing.
Short positioning tells a complicated story. At 19.6% of the free float, the short base remains substantial, but the direction of travel has been lower. Shares short fell nearly 5% over the past week and are down roughly 5% over the past month, suggesting some bears have been covering into the price weakness rather than pressing new positions. The ORTEX short score, at 73.5 out of 100, is elevated but has actually eased from a peak above 74 earlier in October, consistent with that modest covering trend. Critically, the borrow market is relaxed. Availability runs at 312%, meaning roughly three shares are available to lend for every one already borrowed. Cost to borrow is just 0.49%, a multi-month low. Squeeze pressure is essentially absent: there is no scarcity in the lending pool.
Options positioning has shifted meaningfully. The put/call ratio has dropped to 1.42, more than two standard deviations below its 20-day average of 1.55. That might look like bullish repositioning, but the 20-day average itself has been persistently elevated, and the 52-week high stands at 2.45. What the move actually reflects is a roll-off of accumulated downside hedges rather than fresh call buying, consistent with a stock that has already fallen 33% in a month. Defensive positioning has eased, not reversed.
The Street remains almost uniformly bullish on paper, but the targets have been cut hard. Stifel, as recently as September 14, slashed its price target from $48 to $30 while maintaining a Buy rating. JPMorgan had already cut from $52 to $46 in August. With the stock now at $6.58, the mean analyst target of $36.50 is roughly five times the current price. That gap carries a caveat: targets from Citigroup ($59) and JPMorgan ($46) reflect the state of the business in August 2026, before the stock shed another 30%-plus. The directional message is still bullish consensus, but the targets are disconnected from where the shares trade and should be read with caution until updated. Goldman Sachs, which cut to $27 in March, looks closest to the current regime, though even that is four times today's price.
The bull case rests on two assets. Palazestrant (OP-1250) showed encouraging signals in ESR1 wild-type disease, with the OPERA-01 combination trial with Pfizer's atirmociclib fully enrolled. OP-3136 delivered 68% tumor shrinkage in 19 evaluable patients with no dose-limiting toxicities, and the Bayer collaboration extends its reach into metastatic castration-resistant prostate cancer. Cash of $461M is modeled to fund operations into 2028. The bear case is straightforward: no approved products, operating expenses of $67.2M per quarter, a delay in topline OPERA-01 data pushes any palazestrant commercialization to 2028 at the earliest, and modeled 2028 revenues of only $66M leave the company deeply loss-making for years. The EPS outlook factor ranks in just the 7th percentile for forward year-on-year growth, and the short score rank sits in the bottom decile at 9.
FMR (Fidelity) is the largest institutional holder at 13.9% of shares, adding 1.76 million shares as of September 30. BlackRock added 1.06 million shares in the same period. Both are passive or index-adjacent flows, but the direction is incrementally supportive at the margin. On the insider side, the most recent open-market activity was discretionary selling. Director Cyrus Harmon sold 25,000 shares across two sessions in late July at prices around $11.60 to $11.71, and the company's Chief Operating and Financial Officer sold 100,000 shares at $28.73 in January. There has been no open-market buying recorded in the recent window. The 90-day net insider position runs to a net sale of approximately $291,000.
The next scheduled earnings event falls on November 9. Historical reactions have been one-sided: the last four prints produced moves of -12.6%, -13.4%, +3.5%, and -6.7% on the first day, with the two August 2026 events (both logged separately around the same catalyst) averaging a loss of roughly 13% on the day and around 11% over the following five sessions. Whether the BVF 13D filing changes the dynamic around that print, or whether it reflects a longer-term thesis about pipeline value independent of the near-term data calendar, is the question worth watching into November 9.
See the live data behind this article on ORTEX.
Open OLMA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
